MyFinsight
Home
Blog
About
Contact
Download
Download image
Proceeds from issuance of
common stock, net of...
$15,655,192
Net cash provided by
financing activities
$15,308,695
Canceled cashflow
$346,497
Net increase in cash
$4,824,243
Canceled cashflow
$10,484,452
Payment of offering
costs
$346,497
Amortization of right-of-use
assets
$79,396
Accrued expenses
$2,340
Net cash used in
operating activities
-$10,484,452
Canceled cashflow
$81,736
Prepaid expenses
$6,253,298
Net loss for the year
-$4,225,106
Lease liabilities
-$85,210
Accounts payable
-$2,574
Back
Back
Cash Flow
source: myfinsight.com
Curanex Pharmaceuticals Inc (CURX)
Curanex Pharmaceuticals Inc (CURX)